Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 1998

View Archived Issues

FK-506: a topical agent for the treatment of moderate to severe atopic dermatitis

Photogen announces results from animal studies on activation process of photodynamic agents

PPL reports expression of FIX at high concentrations in milk of transgenic sheep

New antiasthmatic agents claimed by Byk Gulden

Life Medical Sciences receives FDA approval to begin Repel-CV trials

Method of detecting HAV infection available for licensing from NIH

Progenitor, CAT establish gene-to-clinic collaboration

Isis and Zeneca collaborate on oligonucleotide manufacturing; fomivirsen filing in sight

Coulter completes patient enrollment in Bexxar phase III trial

PathoGenesis seeks Canadian approval for TOBI in CF

CTL establishes antigen discovery collaboration with University of Tubingen

Compounds with high binding affinity for the 5-HT7 receptor described by Meiji Seika

New antitumor agents discovered by Toagosei

Antiplatelet agents disclosed by Nippon Steel

Selective factor Xa inhibitors in development at Banyu

Spotlight on dual-action ACE/NEP inhibitors

New agents for PDT reported by Yeda

CytoMed and UCB join forces to develop antiinflammatory therapeutics

Salix Holdings name change

ST-630 successfully completes phase Ia trial for osteoporosis

Hoechst discovers inhibitors of various inflammatory mediators

New retinoid-like compounds discovered at Allergan

NIH will license out new technology for studying bone metabolism

Angiogenesis-inhibitory monokine available for licensing from NIH

Novel treatment for red blood cell disorders available for licensing

Ribozyme, Parke-Davis collaboration confirmed

Synaptic licenses technology for BPH treatment to Glaxo Wellcome

UPMC leads the way in gene therapy for musculoskeletal disorders

UPMC studies feasibility of gene therapy for osteoporosis

Gene therapy for treating growth hormone deficiencies

VEGF gene medicine incorporating DOTMA enters phase II testing

Neurogen describes treatment for stress-related disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...